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ABSTRACT
Introduction: We performed a multicentre
evaluation of the Elecsys Anti-SARS-CoV-2
immunoassay (Roche Diagnostics), an assay
utilising a recombinant protein representing
the nucleocapsid (N) antigen, for the in vitro
qualitative detection of antibodies to severe
acute respiratory syndrome coronavirus 2
(SARS-CoV-2).
Methods: Specificity was evaluated using ser-
um/plasma samples from blood donors and
routine diagnostic specimens collected before
September 2019 (i.e., presumed negative for
SARS-CoV-2-specific antibodies); sensitivity was
evaluated using samples from patients with
polymerase chain reaction (PCR)-confirmed
SARS-CoV-2 infection. Point estimates and 95%
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confidence intervals (CIs) were calculated.
Method comparison was performed versus
commercially available assays.
Results: Overall specificity for the Elecsys Anti-
SARS-CoV-2 immunoassay (n = 9575) was 99.85%
(95% CI 99.75–99.92): blood donors (n = 6714;
99.82%), routine diagnostic specimens (n = 2861;
99.93%), pregnant women (n = 2256; 99.91%),
paediatric samples (n = 205; 100.00%). The Elec-
sys Anti-SARS-CoV-2 immunoassay demonstrated
significantly higher specificity versus LIAISON
SARS-CoV-2 S1/S2 IgG (99.71% vs. 98.48%),
EUROIMMUN Anti-SARS-CoV-2 IgG (100.00% vs.
94.87%), ADVIA Centaur SARS-CoV-2 Total
(100.00% vs. 87.32%) and iFlash SARS-CoV-2 IgM
(100.00% vs. 99.58%) assays, and comparable
specificity to ARCHITECT SARS-CoV-2 IgG
(99.75% vs. 99.65%) and iFlash SARS-CoV-2 IgG
(100.00% vs. 100.00%) assays. Overall sensitivity
for Elecsys Anti-SARS-CoV-2 immunoassay sam-
ples drawn at least 14 days post-PCR confirmation
(n = 219) was 93.61% (95% CI 89.51–96.46). No
statistically significant differences in sensitivity
were observed between the Elecsys Anti-SARS-
CoV-2 immunoassay versus EUROIMMUN Anti-
SARS-CoV-2 IgG (90.32% vs. 95.16%) and
ARCHITECT SARS-CoV-2 IgG (84.81% vs.
87.34%) assays. The Elecsys Anti-SARS-CoV-2
immunoassay showed significantly lower sensi-
tivity versus ADVIA Centaur SARS-CoV-2 Total
(85.19% vs. 95.06%) and iFlash SARS-CoV-2 IgG
(86.25% vs. 93.75%) assays, but significantly
higher sensitivity versus the iFlash SARS-CoV-2
IgM assay (86.25% vs. 33.75%).
Conclusion: The Elecsys Anti-SARS-CoV-2
immunoassay demonstrated very high specificity
and high sensitivity in samples collected at least
14 days post-PCR confirmation of SARS-CoV-2
infection, supporting its use to aid in determina-
tion of previous exposure to SARS-CoV-2.
Keywords: SARS-CoV-2; COVID-19;
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Clinical performance; Specificity; Sensitivity;
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Key Summary Points
Why carry out this study?
The coronavirus disease 2019 (COVID-19)
pandemic has prompted the rapid
development of serological assays to
detect prior exposure to severe acute
respiratory syndrome coronavirus 2
(SARS-CoV-2); however, reliable
information on the relative performance
of these assays in a wide range of settings
is urgently needed to better inform
morbidity rates and virus containment
measures.
The Elecsys Anti-SARS-CoV-2
immunoassay (Roche Diagnostics), which
utilises a recombinant protein
representing the nucleocapsid
(N) antigen, was developed to provide an
accurate and reliable method for the
detection of antibodies to SARS-CoV-2.
The aims of this multicentre study were to
provide detailed evidence on the clinical
performance of the Elecsys Anti-SARS-
CoV-2 immunoassay and compare the
results to other commercially available
assays.
What was learned from the study?
The Elecsys Anti-SARS-CoV-2
immunoassay demonstrated a very high
specificity (99.85% [95% CI 99.75–99.92])
in blood donor and routine diagnostic
specimens, and high sensitivity (93.61%
[95% CI 89.51–96.46]) in samples
collected at least 14 days post-PCR
confirmation of SARS-CoV-2 infection;
specificity and sensitivity of the Elecsys
Anti-SARS-CoV-2 immunoassay were
comparable to several other commercially
available assays.
These results support use of the Elecsys
Anti-SARS-CoV-2 immunoassay as a tool
to aid in determination of an immune
response following previous exposure to
SARS-CoV-2 in a wide variety of settings.
C. Niederhauser





As of 16 March 2021, there have been more
than 119 million confirmed cases worldwide of
coronavirus disease 2019 (COVID-19), includ-
ing over 2.6 million deaths, caused by infection
with the novel severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) [1–3]. SARS-
CoV-2 is an enveloped, non-segmented, single-
stranded RNA virus that shares similarities with
other coronaviruses in the expression of its
genome, which encodes 16 non-structural pro-
teins and four structural proteins, known as the
spike (S), envelope (E), membrane (M) and
nucleocapsid (N) antigens [4, 5]. Individuals
infected with SARS-CoV-2 may exhibit a range
of respiratory symptoms, including a persistent
cough, shortness of breath, fever and fatigue
[2, 6]. Although up to 80% of infections are
mild or asymptomatic, 15% are severe, requir-
ing oxygen, and 5% are critical, requiring ven-
tilation [6]. Symptomatic and pre-symptomatic
transmission of SARS-CoV-2, occurring via
contact with infected respiratory droplets and
contaminated surfaces, is thought to play a
greater role in the spread of the virus than
asymptomatic transmission [7, 8].
Reverse transcriptase polymerase chain reac-
tion (RT-PCR) is the current gold standard for
detection of SARS-CoV-2 RNA in sputum gath-
ered from patient nasopharyngeal or oropha-
ryngeal swabs, which typically have high viral
titres during the first few days of infection [9].
Recent evidence suggests that whilst the clinical
sensitivity of PCR remains very high during the
first few days after initial onset of symptoms, it
then decreases over time, dropping from more
than 90% over the first 5 days, to 70–71%
between days 9–11, and 30% on day 21 follow-
ing onset of symptoms [10]. Conversely, the
clinical sensitivity of serological tests has been
shown to increase over time following initial
onset of symptoms, from more than 50% at
day 7, to more than 80% at day 12, and finally
100% at day 21, using an in-house enzyme-
linked immunosorbent assay (Massachusetts
General Hospital, Boston, MA, USA and the
Ragon Institute of MGH, MIT and Harvard,
Cambridge, MA, USA) [10]. Therefore, it is
possible that complementary, time-dependent
use of PCR and serological testing will increase
reliability when determining prior exposure to
SARS-CoV-2 infection, which could better
inform morbidity rates and virus containment
measures.
The Elecsys Anti-SARS-CoV-2 electro-
chemiluminescence immunoassay (Roche
Diagnostics International Ltd, Rotkreuz,
Switzerland) was developed to provide an
accurate method for the in vitro qualitative
detection of high-affinity antibodies to SARS-
CoV-2 [11]. The clinical performance of the
newly launched Elecsys Anti-SARS-CoV-2 sero-
logical assay is undergoing evaluation; however,
high specificity (99.8%) and sensitivity (99.5%)
were previously observed in samples with prior
PCR-confirmed SARS-CoV-2 infection, support-
ing its use as a tool for identification of past
SARS-CoV-2 infection [12].
This multicentre study was conducted to
further evaluate the specificity and sensitivity of
the Elecsys Anti-SARS-CoV-2 immunoassay and




This retrospective, non-interventional study to
evaluate the performance of the Elecsys Anti-
SARS-CoV-2 immunoassay was conducted at six
European sites: four in Germany (Augsburg,
Berlin, Hagen and Heidelberg), one in Switzer-
land (Bern) and one in Austria (Innsbruck). The
Elecsys Anti-SARS-CoV-2 immunoassay was
evaluated using serum/plasma samples from
blood donors and routine diagnostic specimens
that were presumed negative for SARS-CoV-2-
specific antibodies (specificity) and samples
from patients with PCR-confirmed SARS-CoV-2
infection (sensitivity). The first sample was tes-
ted on 20 May 2020 and the last sample was
tested on 2 September 2020.
This study was conducted in accordance
with the study protocol provided by Roche
Diagnostics and in accordance with the princi-
ples of the Declaration of Helsinki. All human
Infect Dis Ther
samples utilised were anonymised, frozen,
residual samples for which no ethical approval
was required or waiver was required in accor-
dance with local legislation from ZEKO (Central
Ethics Commission at the German Medical
Association). A statement was obtained from
the Ethics Committee of the Landesärztekam-
mer Bayern confirming that there are no
objections to the coherent use of anonymised
residual samples. The study protocol was sub-
mitted to institutional review boards at study
sites in Innsbruck (Austria) and Bern (Switzer-
land) prior to study initiation; ethical approval
was granted for Innsbruck and a waiver granted
for Bern.
Assay
The Elecsys Anti-SARS-CoV-2 electrochemilu-
minescence immunoassay was developed for
the in vitro qualitative detection of antibodies
to SARS-CoV-2 in human serum and plasma. It
utilises a recombinant protein representing the
nucleocapsid (N) antigen of the virus in a dou-
ble-antigen sandwich test format, which favours
detection of mature, high-affinity antibodies to
SARS-CoV-2 [11, 13]. The Elecsys Anti-SARS-
CoV-2 immunoassay is intended for use on
cobas e analysers; total duration of the
immunoassay is 18 min. The analyser auto-
matically calculates a cut-off based on the
measurement of two calibrators, one negative
(ACOV2 Cal1) and one positive (ACOV2 Cal2).
The result of a sample is given as either ‘reac-
tive’ or ‘non-reactive’ in the form of a cut-off
index (COI).
In this study, measurements determined
using the Elecsys Anti-SARS-CoV-2 immunoas-
say were interpreted according to the manu-
facturer’s instructions. Samples with a
COI\1.0 were considered non-reactive and
deemed negative for anti-SARS-CoV-2 antibod-
ies, while those with a COI C 1.0 were consid-
ered reactive and deemed positive for anti-SARS-
CoV-2 antibodies [13].
Specificity Analysis
The specificity of the Elecsys Anti-SARS-CoV-2
immunoassay was evaluated at five sites using
anonymised, frozen, residual samples from
blood donor screening and routine diagnostic
testing, including pregnancy screening and
paediatric samples. Four sites (Augsburg, Hagen,
Heidelberg and Bern) provided serum and/or
plasma samples and performed testing using
cobas e 601 and 801 analysers (Roche Diagnos-
tics International Ltd, Rotkreuz, Switzerland);
samples from Innsbruck were sent to Augsburg
for measurement. All samples were obtained
before September 2019 and were presumed
negative for SARS-CoV-2-specific antibodies.
Details of the cohorts enrolled and tested across
the five sites are summarised in the Supple-
mentary Material (Supplementary Table 1).
Sensitivity Analysis
Evaluation of the sensitivity of the Elecsys Anti-
SARS-CoV-2 immunoassay was conducted at
three sites in Germany (Augsburg, Heidelberg
and Berlin) using anonymised, frozen, residual
serum or plasma samples. All samples were
single or sequential and confirmed positive for
SARS-CoV-2 using PCR. Augsburg and Heidel-
berg included samples drawn from outpatients.
Heidelberg also included samples from
employees of MVZ Labor Limbach and hospi-
talised patients, including a subset from
patients receiving dialysis. All samples provided
by the study site in Berlin were collected from
hospitalised patients, including a subset from
patients monitored in the intensive care unit
(ICU).
The sensitivity of the Elecsys Anti-SARS-CoV-
2 immunoassay was evaluated on cobas e 601
and 801 analysers (Roche Diagnostics Interna-
tional Ltd, Rotkreuz, Switzerland). All samples
were categorised by the week in which they
were drawn following a positive PCR result, and
grouped as follows: 0–6 days, 7–13 days, or at
least 14 days post-PCR confirmation. For
sequential samples, blood draws were per-
formed over a period of minimum 2 to maxi-
mum 64 days, up to day 78. If more than one
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sample per patient was collected per time
interval, only the last specimen per patient was
included in the sensitivity calculation. For
example, if blood was drawn from a patient on
day 3, day 7, day 10, day 14 and day 21, only
values from day 3, day 10 and day 21 would be
included in the 0–6, 7–13 and at least 14 days
post-PCR confirmation groups, respectively.
Method Comparison
Specificity and sensitivity results determined
using the Elecsys Anti-SARS-CoV-2 immunoas-
say were compared with those calculated for
other commercially available SARS-CoV-2
assays, as available at each study site. Com-
parator platforms included LIAISON SARS-CoV-
2 S1/S2 IgG assay (DiaSorin, Saluggia, Italy);
EUROIMMUN Anti-SARS-CoV-2 IgG assay
(EUROIMMUN Medizinische Labordiagnostika
AG, Luebeck, Germany); ARCHITECT SARS-
CoV-2 IgG assay (Abbott Laboratories, Abbott
Park, IL, USA); ADVIA Centaur SARS-CoV-2
Total assay (Siemens Healthcare GmbH, Erlan-
gen, Germany); and iFlash SARS-CoV-2 IgG and
IgM assays (Shenzhen YHLO Biotech Co., Ltd,
Shenzhen, China). Results for each comparator
assay were interpreted using cut-off values pro-
vided in the respective manufacturer’s package
insert. For a breakdown of comparator assays by
study site, please refer to the Supplementary
Material (Supplementary Table 2). For method
comparison of sensitivity between the Elecsys
Anti-SARS-CoV-2 immunoassay and the LIAI-
SON SARS-CoV-2 S1/S2 IgG assay, results were
excluded because of the small sample size.
For all comparator assays, results considered
‘equivocal’ or ‘borderline’ per the cut-off values
provided in the manufacturer’s package insert
were grouped into a ‘grey zone’. For assays with
results that were included in the grey zone, two
calculations were performed: in the first, all
samples with grey zone results were excluded
from the analysis; in the second, all grey zone
results were interpreted as reactive.
Overall percentage agreement (OPA)
between the Elecsys Anti-SARS-CoV-2
immunoassay and the comparator assays was
also calculated. For presumed negative samples,
the same samples were used for specificity
analysis and comparison of those results
between methods and calculation of OPA. For
confirmed positive samples, all samples with a
valid measurement from both the Elecsys Anti-
SARS-CoV-2 immunoassay and the comparator
assay were included in the analysis; the OPA
calculation was performed independently of the
time point of blood draw.
Statistical Analysis
According to a previously published formulae
[14], sample sizes of n = 3435–20,964 for the
specificity analyses (assuming a specificity of
0.998) and n = 32–50 for the sensitivity analyses
(assuming a sensitivity of 0.999) would be
required to ensure a significance level of 0.05
and power of 0.8. Point estimates and 95%
confidence intervals (CIs; two sided) were cal-
culated using the exact method for specificity
and sensitivity. For the specificity analysis,
samples were grouped into those obtained from
archived blood donations (group A) and those
from archived routine diagnostic specimens
(group B). For the method comparison, two-
sided Wald CIs were calculated for the differ-
ences between estimated specificities and sen-
sitivities for the Elecsys Anti-SARS-CoV-2
immunoassay and comparator assays, as rec-
ommended by Wenzel and Zapf [15]. If these




Specificity results for the overall sample cohort
(n = 9575) and by analysis group are sum-
marised in Table 1. Using an assay COI of 1.0
resulted in an overall specificity of 99.85% (95%
CI 99.75–99.92) in samples obtained across all
five sites. Among 6714 serum and/or plasma
samples from blood donors and 2861 serum
and/or plasma samples from routine diagnostic
samples, specificity was 99.82% (95% CI
99.69–99.91) and 99.93% (95% CI 99.75–99.99),
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respectively. Among 2256 samples from preg-
nant women, specificity was 99.91% (95% CI
99.68–99.99). Among 205 paediatric samples,
specificity was 100.00% (95% CI 98.22–100.00).
Across groups A (blood donors) and B (routine
diagnostic specimens), a total of 14 reactive
samples were detected (group A, n = 12;
group B, n = 2).
In total, 9561 of the presumed SARS-CoV-2
antibody negative samples tested had a COI\
1.0; the vast majority of these had COIs\ 0.1
(n = 9064; Fig. 1). Only 14 samples had a COI
C 1.0 (pre-specified cut-off for reactivity).
Sensitivity Analysis
A total of 806 single and sequential SARS-CoV-2
PCR-confirmed positive samples from 255
patients across the three study sites were
Table 1 Summary of specificity results for the Elecsys Anti-SARS-CoV-2 immunoassay in blood donor and routine
diagnostic samples














1048 5 1043 99.52 (98.89–99.84)
Germany (Hagen), no seasonal
selection
2625 2 2623 99.92 (99.73–99.99)
Switzerland (Bern), no seasonal
selection
3041 5 3036 99.84 (99.62–99.95)
Switzerland (Bern), outside
influenza season
2003 2 2001 99.90 (99.64–99.99)
Switzerland (Bern), influenza
season
1038 3 1035 99.71 (99.16–99.94)





400 0 400 100.00 (99.08–100.00)
Germany (Augsburg),
pregnancy
1498 2 1496 99.87 (99.52–99.98)
Germany (Heidelberg),
pregnancy
758 0 758 100.00 (99.51–100.00)
Germany (Augsburg and
Heidelberg), pregnancy
2256 2 2254 99.91 (99.68–99.99)
Germany (Heidelberg),
paediatrics
205 0 205 100.00 (98.22–100.00)
All 2861 2 2859 99.93 (99.75–99.99)
CI confidence interval, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
a Samples from Innsbruck were analysed at Augsburg
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included in this analysis (Supplementary Mate-
rial; Supplementary Table 3). Twenty samples
were excluded because of an unclear or negative
PCR result, missing Elecsys Anti-SARS-CoV-2
immunoassay result, or incorrect inclusion in
the sample cohort. All samples from the study
site in Augsburg were from outpatients. Of the
samples from the study sites in Heidelberg,
approximately half were drawn from dialysis
patients. All samples from the study site in
Berlin were drawn from hospitalised patients;
approximately 60% of these samples were
drawn from patients in the ICU.
Fig. 1 COI distribution in patient samples presumed negative for SARS-CoV-2 antibodies (n = 9575). COI cut-off index,
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
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Overall sensitivity of the Elecsys Anti-SARS-
CoV-2 immunoassay was 93.61% (95% CI
89.51–96.46) in samples collected at least
14 days post-PCR confirmation of SARS-CoV-2
infection (n = 219; Table 2); sensitivity was
43.14% (95% CI 29.35–57.75) at 0–6 days
(n = 51) and 84.00% (95% CI 70.89–92.83) at
7–13 days post-PCR confirmation (n = 50).
Fourteen samples collected at least 14 days post-
PCR confirmation were found to be non-reac-
tive: 12 from Heidelberg, one from Augsburg,
and one from Berlin. Site-specific calculations
showed that sensitivity of the Elecsys Anti-
SARS-CoV-2 immunoassay was highest at
Augsburg (98.94% [95% CI 94.21–99.97]) in
samples drawn at least 14 days post-PCR con-
firmation, and lowest at Augsburg in samples
drawn 0–6 days post-PCR confirmation (33.33%
[95% CI 0.84–90.57]). For all three sites, sensi-
tivity was highest at at least 14 days post-PCR




Method comparison was performed using
934–2039 samples per comparison. The speci-
ficity of the Elecsys Anti-SARS-CoV-2
immunoassay was similar or higher than the
specificity of all tested comparator assays
(Table 3). Statistically significant differences
were observed between the Elecsys Anti-SARS-
CoV-2 immunoassay versus the following
comparator assays: LIAISON SARS-CoV-2 S1/S2
IgG (n = 2039, 99.71% vs. 98.48%, difference
1.23%); EUROIMMUN Anti-SARS-CoV-2 IgG
(n = 956, 100.00% vs. 94.87%, difference
5.13%); ADVIA Centaur SARS-CoV-2 Total
(n = 962, 100.00% vs. 87.32%, difference
12.68%); and iFlash SARS-CoV-2 IgM (n = 962,
100.00% vs. 99.58%, difference 0.42%). No
statistically significant differences were
observed between the Elecsys Anti-SARS-CoV-2
immunoassay versus the following comparator
assays: ARCHITECT SARS-CoV-2 IgG (n = 2006,
99.75% vs. 99.65%, difference 0.10%); and
iFlash SARS-CoV-2 IgG (n = 962, 100.00% vs.
100.00%, difference 0%).
Sensitivity
Method comparison was performed using
79–124 samples drawn at least 14 days post-PCR
confirmation per comparison across the three
study sites. Across all assays evaluated, sensi-
tivity was highest for the EUROIMMUN Anti-
SARS-CoV-2 IgG assay for samples drawn at least
14 days post-PCR confirmation at 95.16% (95%
Table 2 Sensitivity of the Elecsys Anti-SARS-CoV-2 immunoassay by time interval post-PCR confirmation
Time interval (days post-PCR
confirmation)
Sensitivity, % (95% CI)
n/N































CI confidence interval, PCR polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
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CI 89.77–98.20; Table 4). No statistically signif-
icant differences in sensitivity for samples
drawn at least 14 days post-PCR confirmation
were observed between the Elecsys Anti-SARS-
CoV-2 immunoassay and the EUROIMMUN
Anti-SARS-CoV-2 IgG (n = 124, 90.32% vs.
95.16%, difference - 4.84%) and ARCHITECT
SARS-CoV-2 IgG (n = 79, 84.81% vs. 87.34%,
difference - 2.53%) assays. The Elecsys Anti-
SARS-CoV-2 immunoassay showed significantly
lower sensitivity versus the ADVIA Centaur
SARS-CoV-2 Total (n = 81, 85.19% vs. 95.06%,
difference - 9.88%) and iFlash SARS-CoV-2 IgG
(n = 80, 86.25% vs. 93.75%, difference
- 7.50%) assays, but significantly higher sensi-
tivity versus the iFlash SARS-CoV-2 IgM assay
(n = 80, 86.25% vs. 33.75%, difference 52.50%).
Agreement Rates
Agreement rates (OPA) for the Elecsys Anti-
SARS-CoV-2 immunoassay versus comparator
assays in presumed SARS-CoV-2 antibody neg-
ative samples ranged between 87.32% and
100.00%, and in SARS-CoV-2 PCR-confirmed
Table 3 Summary of specificity values for the Elecsys Anti-SARS-CoV-2 immunoassay and comparator assays in presumed















































N/A 962 99.58 (98.94–99.89) 0.42 (0.01–0.82) Yes
100.00 (99.62–100.00)a
CI confidence interval, IgG immunoglobulin G, IgM immunoglobulin M, N/A not applicable, SARS-CoV-2 severe acute
respiratory syndrome coronavirus 2
a Measurements taken on the Elecsys Anti-SARS-CoV-2 immunoassay using the same samples
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positive samples ranged between 44.22% and
93.80% (Table 5).
DISCUSSION
There is an urgent unmet need for highly sen-
sitive serological assays for detecting antibodies
to SARS-CoV-2 in order to aid identification of
individuals previously exposed to the virus and
inform containment procedures [16, 17]. In this
multicentre study, the Elecsys Anti-SARS-CoV-2
immunoassay demonstrated a very high speci-
ficity of 99.85% across a large cohort of blood
donor and routine diagnostic samples and a
high overall sensitivity of 93.61% in samples
collected at least 14 days post-PCR confirmation
of SARS-CoV-2 infection. Specificity and
sensitivity of the Elecsys Anti-SARS-CoV-2
immunoassay were comparable to several other
commercially available SARS-CoV-2 assays tes-
ted. These findings provide broader evidence for
the favourable performance of the assay across
different diagnostic laboratories and support its
use as a tool to aid the determination of previ-
ous exposure to SARS-CoV-2 infection.
The very high overall specificity reported
here (99.85%) for the Elecsys Anti-SARS-CoV-2
immunoassay corresponds to that reported by
the manufacturer (99.80%) [13] and in previous
studies using samples drawn pre-COVID-19
(98.00–100%) [12, 18–21]. The overall sensitiv-
ity of the Elecsys Anti-SARS-CoV-2 immunoas-
say in samples collected at least 14 days post-
PCR confirmation of SARS-CoV-2 infection in
the present study (93.61%) was similar to that
Table 4 Summary of sensitivity values for the Elecsys Anti-SARS-CoV-2 immunoassay and comparator assays determined





































N/A 80 33.75 (23.55–45.19) 52.50 (40.51 to 64.49) Yes
86.25 (76.73–92.93)b
CI confidence interval, IgG immunoglobulin G, IgM immunoglobulin M, N/A not applicable, PCR polymerase chain
reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
a For method comparison of sensitivity between the Elecsys Anti-SARS-CoV-2 immunoassay and the LIAISON SARS-
CoV-2 S1/S2 IgG assay, results were excluded because of the small sample size
b Measurements taken on the Elecsys Anti-SARS-CoV-2 immunoassay using the same samples
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reported in a previous study in PCR-confirmed
SARS-CoV-2 infected samples collected 14 days
post-symptom onset (92.0%) [20], but lower
than that reported in the manufacturer’s pack-
age insert (99.5%) [13]. A potential reason for
this may be differences in assay sensitivity
between the sites in the present study; in par-
ticular, the lower sensitivity calculated for
samples analysed at Heidelberg (85.71%), com-
pared with Augsburg (98.94%) and Berlin
(97.56%). The samples analysed at Berlin were
taken from hospitalised patients, including a
subset of samples from patients monitored in
the ICU, for whom blood draws were closely
monitored. In contrast, the majority of samples
tested at Augsburg and Heidelberg were from
outpatients. Disease severity in ICU patients
was likely far greater than that of non-hospi-
talised patients infected with SARS-CoV-2,
which may exacerbate immune response and
increase the likelihood of a positive test result
from the Elecsys Anti-SARS-CoV-2 immunoas-
say [22–24]. It is possible that the observed dif-
ference in sensitivity performance of the Elecsys
Anti-SARS-CoV-2 immunoassay between study
sites was partly caused by the pre-characterisa-
tion and selection of cohorts applied at each
site. However, given the unprecedented situa-
tion of the ongoing COVID-19 pandemic, the
clinical heterogeneity included in this study
Table 5 Agreement rates for the Elecsys Anti-SARS-CoV-2 immunoassay and comparator assays in presumed SARS-CoV-
2 antibody negative and PCR-confirmed positive samples
Assay Elecsys Anti-SARS-CoV-2
Sample type Samples tested,
n
Overall agreement, % (95%
CI)
LIAISON SARS-CoV-2 S1/S2 IgG Presumed SARS-CoV-2
negative
2039 98.19 (97.51–98.72)






PCR-confirmed positive 710 93.80 (91.77–95.46)
ARCHITECT SARS-CoV-2 IgG Presumed SARS-CoV-2
negative
2006 99.40 (98.96–99.69)
PCR-confirmed positive 147 91.16 (85.35–95.21)
ADVIA Centaur SARS-CoV-2 Total Presumed SARS-CoV-2
negative
962 87.32 (85.05–89.36)
PCR-confirmed positive 149 83.89 (76.99–89.40)
iFlash SARS-CoV-2 IgG Presumed SARS-CoV-2
negative
962 100.00 (99.62–100.00)
PCR-confirmed positive 147 90.48 (84.54–94.69)
iFlash SARS-CoV-2 IgM Presumed SARS-CoV-2
negative
962 99.58 (98.94–99.89)
PCR-confirmed positive 147 44.22 (36.04–52.63)
CI confidence interval, IgG immunoglobulin G, IgM immunoglobulin M, N/A not applicable, PCR polymerase chain
reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
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should be considered a strength rather than a
limitation. Moreover, approximately 50% of all
samples tested at Heidelberg were from patients
undergoing dialysis, in whom infections are one
of the main causes of morbidity and mortality
due to immunodeficiency associated with end-
stage renal disease [25–27]. Therefore, it is less
likely that these patients were able to mount a
detectable antibody response to SARS-CoV-2
[28, 29]. In the present study, 10/12 non-reac-
tive samples collected at least 14 days post-PCR
confirmation at Heidelberg were from patients
receiving dialysis. These findings support the
use of PCR confirmation alongside serological
testing for immunocompromised patients to
ensure an accurate test result.
The Elecsys Anti-SARS-CoV-2 immunoassay
demonstrated a very high specificity of 99.91%
in samples from pregnant women. Accurate
serological assays for SARS-CoV-2 are especially
important for use in pregnant women, who may
have increased susceptibility to viral respiratory
infections because of altered immune status
[30]. At present, there are limited data available
on the performance of other commercially
available serological assays for SARS-CoV-2 in
pregnant women. Rushworth et al. conducted a
performance evaluation of the Mount Sinai
SARS-CoV-2 IgG antibody ELISA and observed
no false positive results in a cohort of negative
control samples (n = 50) drawn from presumed
healthy pregnant women pre-COVID-19 [31]. In
the present study, two reactive results were
observed in pre-COVID-19 samples from preg-
nant women, which could be the result of an
unknown cross-reactant. A very high specificity
of 100% for the Elecsys Anti-SARS-CoV-2
immunoassay was also observed in the present
study in a paediatric cohort. However, it should
be noted that the statistical significance of these
results is not very powerful because of the rela-
tively small number of samples in this cohort
(n = 205) and further investigation is warranted.
In the present study, the sensitivity of the
Elecsys Anti-SARS-CoV-2 immunoassay was
lowest 0–6 days post-PCR confirmation at
43.14%, before increasing to 93.61% for sam-
ples drawn at least 14 days post-PCR confirma-
tion. This trend towards increased sensitivity
over time following PCR confirmation was
observed across all three sites and is in accor-
dance with previous research [10, 12, 21].
However, in a similar cohort of SARS-CoV-2
PCR-confirmed positive samples, Oved et al.
previously found that approximately 5% of
patients remained seronegative at least 14 days
post-PCR confirmation, and thus did not sero-
convert [32]. These individuals would not have
a positive result on a serological assay. There-
fore, it is important to consider this phe-
nomenon when evaluating these results, as it
could affect the trends observed herein.
In the present method comparison analysis,
the specificity of the Elecsys Anti-SARS-CoV-2
immunoassay was similar to or higher than that
of the comparator assays tested. The sensitivity
of the Elecsys Anti-SARS-CoV-2 immunoassay
was also similar to the EUROIMMUN Anti-SARS-
CoV-2 IgG and ARCHITECT SARS-CoV-2 IgG
assays, but higher than that of the iFlash SARS-
CoV-2 IgM assay, and lower than that of the
ADVIA Centaur SARS-CoV-2 Total and iFlash
SARS-CoV-2 IgG assays. It is important to note,
however, that the available assays differ in
terms of their assay design (e.g. antibody class)
and the viral antigens they detect (e.g. spike
protein or nucleocapsid protein). For example,
the format of the Elecsys Anti-SARS-CoV-2
immunoassay requires binding of an antibody
in the patient sample to two specific antigens,
and thus favours preferential detection of
mature, high-affinity antibodies characteristic
of the late stages of SARS-CoV-2 infection
[11, 13]. In addition, the clinical performance of
serological assays is a compromise between
sensitivity and specificity; whilst some assays
are designed for higher sensitivity, others are
designed for higher specificity.
Importantly, the overall specificity of the
Elecsys Anti-SARS-CoV-2 immunoassay deter-
mined in the present study (99.85%) is compa-
rable with the specificities of other
commercially available assays reported in pre-
vious studies, including the ARCHITECT SARS-
CoV-2 IgG ELISA (99.7%), LIAISON SARS-CoV-2
S1/S2 IgG ELISA (97.9–98.3%) and Elecsys Anti-
SARS-CoV-2 S (99.8–100%) assays
[18, 20, 32–34]. Higher specificity was observed
for the Elecsys Anti-SARS-CoV-2 immunoassay
in the present study than previously reported
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for the EUROIMMUN Anti-SARS-CoV-2 IgG
(96–96.5%) ELISA [20, 35]. The relatively lower
specificities measured for the Elecsys Anti-SARS-
CoV-2 immunoassay and EUROIMMUN Anti-
SARS-CoV-2 IgG ELISA could be attributed to
cross-reactivity with antibodies to adenoviruses
and other human coronaviruses [35]. A recent
study reported no cross-reactivity with the
Elecsys Anti-SARS-CoV-2 immunoassay in
common cold or endemic coronavirus sample
panels [12].
In general, the sensitivity of the comparator
assays tested in the present study is consistent
with previous findings [35–39]. The low sensi-
tivity of the iFlash SARS-CoV-2 IgM assay in the
present study is in accordance with that previ-
ously reported [40]. A potential explanation for
this is the fact that detection of SARS-CoV-2-
specific IgM is limited to very early on in the
infection cascade; only 20% of SARS-CoV-2
infected individuals present IgM before IgG,
and the majority will present both IgM and IgG
in tandem [41]. Some studies have reported the
detection of SARS-CoV-2-specific IgG even
before IgM [42, 43]. Moreover, a 10-month fol-
low-up study showed that assays designed to
detect total antibodies had significantly higher
rates of positive results compared with assays
directed against IgG alone [44]. Taken together,
the clinical value of IgM for diagnosis of
COVID-19 remains unclear [45].
A major strength of this study is the large
cohort of presumed SARS-CoV-2-negative
(n = 9575) and SARS-CoV-2 PCR-confirmed
positive (n = 806) serum and plasma samples
used to evaluate specificity and sensitivity of the
Elecsys Anti-SARS-CoV-2 immunoassay, respec-
tively, across multiple sites in different coun-
tries and patient groups. This ensures that our
data are reliable and can be used to form robust
comparisons with immunoassay performance
data from other studies. To our knowledge, the
present study includes the largest cohort of
samples from pregnant women used to date to
evaluate the performance of a serological assay
for SARS-CoV-2 with regard to specificity.
Existing literature on the performance of com-
mercially available assays for detection of anti-
bodies to SARS-CoV-2 is limited in pregnant
women and paediatric populations; thus,
additional research in these groups is warranted
to further inform clinical decision-making. This
study was performed under accelerated timeli-
nes due to the high scientific value of the data
in the ongoing COVID-19 pandemic, and so
long-term stability data for frozen samples were
not available prior to study initiation. However,
the prolonged stability of IgG antibodies is well
documented and so this should not impact the
present data [46, 47]. For evaluation of sensi-
tivity, the follow-up period for sequential sam-
ples was relatively short (maximum 64 days).
Recent findings suggest that a lack of long-term
follow-up samples may impact the sensitivity of
SARS-CoV-2 serological assays because of the
absence of seroconversion; therefore, inclusion
of long-term samples may be beneficial in future
studies [33, 34].
CONCLUSION
The performance of SARS-CoV-2 antibody
assays in general is of high importance for
public health and may affect political decision-
making in pandemic management. This study
generated additional data on the performance
of the Elecsys Anti-SARS-CoV-2 immunoassay
and provides broader evidence for the very high
specificity of the assay, including in cohorts of
pregnant women and paediatric populations.
The Elecsys Anti-SARS-CoV-2 immunoassay also
demonstrated a high overall sensitivity in sam-
ples collected at least 14 days post-PCR confir-
mation of SARS-CoV-2 infection, which was
comparable to several other commercially
available assays. Our findings support the use of
the Elecsys Anti-SARS-CoV-2 immunoassay as a
tool to aid in determination of previous expo-
sure to SARS-CoV-2.
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